Therapeutic Approaches Targeting Nucleolus in Cancer
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
The nucleolus is a distinct sub-cellular compartment structure in the nucleus. First observed more than 200 years ago, the nucleolus is detectable by microscopy in eukaryotic cells and visible during the interphase as a sub-nuclear structure immersed in the nucleoplasm, from which it is not separated from any membrane. A huge number of studies, spanning over a century, have identified ribosome biogenesis as the main function of the nucleolus. Recently, novel functions, independent from ribosome biogenesis, have been proposed by several proteomic, genomic, and functional studies. Several works have confirmed the non-canonical role for nucleoli in regulating important cellular processes including genome stability, cell-cycle control, the cellular senescence, stress responses, and biogenesis of ribonucleoprotein particles (RNPs). Many authors have shown that both canonical and non-canonical functions of the nucleolus are associated with several cancer-related processes. The association between the nucleolus and cancer, first proposed by cytological and histopathological studies showing that the number and shape of nucleoli are commonly altered in almost any type of cancer, has been confirmed at the molecular level by several authors who demonstrated that numerous mechanisms occurring in the nucleolus are altered in tumors. Recently, therapeutic approaches targeting the nucleolus in cancer have started to be considered as an emerging “hallmark” of cancer and several therapeutic interventions have been developed. This review proposes an up-to-date overview of available strategies targeting the nucleolus, focusing on novel targeted therapeutic approaches. Finally, a target-based classification of currently available treatment will be proposed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Boulon, S., Westman, B. J., Hutten, S., Boisvert, F.-M., & Lamond, A. I. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.024 · Cited by 1,103 · cited 1×
“The nucleolar stress pathway integrates several networks, some of which require the p53 activity while others are independent [13,48].”
BackgroundDiscovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development
Ding, Q., Zhang, Z., Liu, J.-J., Jiang, N., Zhang, J., Ross, T. M., Chu, X.-J., Bartkovitz, D., Podlaski, F., Janson, C., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400487c · Cited by 595 · cited 2×
“Nutlin-1/2/3, RG7112 RG7388 PXN727 PXN822 Nutlins and derivatives Targeting the MDM2-P53 interaction Haematological tumours, solid tumours [98,99]; osteosarcoma, head and neck cancer [100]; pre-clinical models [99]”
BackgroundSignaling to p53: ribosomal proteins find their way
Zhang, Y., & Lu, H. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.09.024 · Cited by 591 · cited 3×
“The p53-dependent nucleolar stress pathway is triggered by several stressing stimuli able to alter the integrity of nucleolus and negatively interfere with ribosome biogenesis leading to the accumulation of p53 (TP53) [13,50].”
BackgroundInfluentialLife on a planet of its own: Regulation of RNA polymerase I transcription in the nucleolus
Grummt, I. (2003) · Genes & Development · doi:10.1101/gad.1098503r · Cited by 540
Pederson, T. (2011) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000638 · Cited by 455 · cited 2×
“However, recently, results from different groups have led to the proposal of a new concept, that of a pluri-functional nucleolus, providing evidence that the nucleolus exerts non-canonical functions independently from ribosome biogenesis [1,13,20].”
BackgroundTranslating p53 into the clinic
Cheok, C. F., Verma, C. S., Baselga, J., & Lane, D. P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.174 · Cited by 381 · cited 9×
“MI-77301 MI-219 Spirooxindole-based compound Targeting the MDM2-P53 interaction Osteosarcoma, acute leukemia, prostate and colon cancer cells [101]; hematologic neoplasms and advanced solid tumors [99]”
BackgroundInfluentialResults of the Phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia
Andreeff, M., Kelly, K. R., Yee, K., Assouline, S., Strair, R., Popplewell, L., Bowen, D., Martinelli, G., Drummond, M. W., Vyas, P., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0481 · Cited by 352 · cited 3×
“Nutlin-1, Nutlin-2, and Nutlin-3, belonging to the Nutlins family, are small molecules, designed to prevent the MDM2-p53 physical interaction, thus further triggering the activation of p53 [98,99].”
BackgroundThe ATM repair pathway inhibits RNA polymerase I transcription in response to chromosome breaks
Kruhlak, M., Crouch, E. E., Orlov, M., Montaño, C., Gorski, S. A., Nussenzweig, A., Misteli, T., Phair, R. D., & Casellas, R. (2007) · Nature · doi:10.1038/nature05842 · Cited by 305 · cited 1×
“In recent years, several proteomics works have demonstrated that numerous onco-proteins and tumor suppressors modulate the RNA Pol I transcription such as the cell cycle check point kinase ATM (ataxia telangiectasia mutated) [119], the kinase ATR (ataxia telangiectasia and Rad3-related”
BackgroundTargeting the MDM2–p53 Protein–Protein Interaction for New Cancer Therapy: Progress and Challenges
Wang, S., Zhao, Y., Aguilar, A., Bernard, D., & Yang, C.-Y. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026245 · Cited by 300 · cited 5×
“MI-77301 MI-219 Spirooxindole-based compound Targeting the MDM2-P53 interaction Osteosarcoma, acute leukemia, prostate and colon cancer cells [101]; hematologic neoplasms and advanced solid tumors [99]”
BackgroundInfluentialRepression of RNA Polymerase I Transcription by the Tumor Suppressor p53
Zhai, W., & Comai, L. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.16.5930-5938.2000 · Cited by 289 · cited 1×
“P53 is able to directly interfere with the assembly of PIC by binding to SL-1 and preventing the SL-1/UBF association [118].”
BackgroundHolzer, P., Masuya, K., Furet, P., Kallen, J., Valat-Stachyra, T., Ferretti, S., Berghausen, J., Bouisset-Leonard, M., Buschmann, N., Pissot-Soldermann, C., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00810 · Cited by 203 · cited 2×
“The CGM097 is a dihydroisoquinolinone derivative under investigation in a phase I clinical trial evaluating the efficacy of CGM097 in p53 wild-type patients with advanced refractory solid tumors [103].”
BackgroundCanon, J., Osgood, T., Olson, S. H., Saiki, A. Y., Robertson, R., Yu, D., Eksterowicz, J., Ye, Q., Jin, L., Chen, A., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0710 · Cited by 152
Schöfer, C., & Weipoltshammer, K. (2018) · Histochemistry and Cell Biology · doi:10.1007/s00418-018-1696-3 · Cited by 83
Wall, M., Poortinga, G., Stanley, K. L., Lindemann, R. K., Bots, M., Chan, C. J., Bywater, M. J., Kinross, K. M., Astle, M. V., Waldeck, K., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0404 · Cited by 64 · cited 2×
“Rapamycin Everolimus mTOR signalling inhibitor Inhibiting mTOR signalling resulting in inhibition of ribosome biogenesis Renal cell carcinoma, breast cancer and lymphoma [96]”
Background
Cited by
Trapotsi, M.-A., Mouchet, E., Williams, G., Monteverde, T., Juhani, K., Turkki, R., Miljković, F., Martinsson, A., Mervin, L., Pryde, K. R., et al. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.2c00076 · Cited by 51
Role of uL3 in the Crosstalk between Nucleolar Stress and Autophagy in Colon Cancer Cells
Pecoraro, A., Carotenuto, P., Franco, B., De Cegli, R., Russo, G., & Russo, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062143 · Cited by 35
“It has been demonstrated that most chemotherapeutic drugs used in colon cancer are able to activate the so-called nucleolar stress response which in turn causes translocation of ribosomal proteins (r-proteins) as ribosome free proteins from the nucleolus to the nucleoplasm [4,5].”
BackgroundSelf-citationSURF2 is a MDM2 antagonist in triggering the nucleolar stress response
Tagnères, S., Santo, P. E., Radermecker, J., Rinaldi, D., Froment, C., Provost, Q., Bongers, M., Capeille, S., Watkins, N., Marcoux, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52659-x · Cited by 15
Metadata
- Authors
- Carotenuto, P., Pecoraro, A., Palma, G., Russo, G., & Russo, A.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2019-09-16
- Volume
- 8
- Issue
- 9
- Pages
- 1090
- ISSN
- 2073-4409 (ISSN-L)
- OpenAlex
- W2972619137
- Cited by
- 81
- References
- 14
- FWCI
- 2.94
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.